October 09, 2015.
According to Mergermarket's Pharma, Medical & Biotech Trend Report Q1-Q3 2015, pharma, medical and biotech (PMB) activity hit its largest year-to-date value on Mergermarket record (since 2001), with 954 transactions worth US$ 367.6bn representing a 46.2% increase by value compared to the same period in 2014. The increase in deal activity has been driven by a surge of M&A within pharma, attracting 268 deals worth US$ 231.5bn, a 93.4% increase compared to the same period last year (251 deals, US$ 119.7bn), says Mergermarket. Biotech, on the other hand, decreased 31.6% by value to US$ 12.6bn (98 deals), down from US$ 18.4bn (111 deals) during year-to-date 2014. "Market turbulence has hit the biotech sector hard," the report states, "with the NASDAQ Biotechnology Index falling 24% since the year’s peak on 20 June. While some bankers and biotech investors say big pharma companies should step up their efforts to acquire assets at a discount, big pharma executives say they are waiting for a sustained downdraft before considering stepping up M&A activities." The US (372 deals, US$ 271.4bn) remains the main attraction for activity targeting the PMB sector, with four out of the top five deals worth US$ 127.9bn acquiring US targets. As a result, US activity took a 73.8% share in global deal value targeting the sector during 2015, up from 60.6% for the same period in 2014. http://www.mergermarket.com/pdf/Mergermarket%20trend%20report.Q1-Q3%202015.PMB.pdf
Can Data and AI Deliver Whole-Person Health?
July 9th 2024Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.